Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Takahito Fukusumi is active.

Publication


Featured researches published by Takahito Fukusumi.


Development Growth & Differentiation | 2013

Adipose-derived mesenchymal stem cells and regenerative medicine

Masamitsu Konno; Atsushi Hamabe; Shinichiro Hasegawa; Hisataka Ogawa; Takahito Fukusumi; Shimpei Nishikawa; Katsuya Ohta; Yoshihiro Kano; Miyuki Ozaki; Yuko Noguchi; Daisuke Sakai; Toshihiro Kudoh; Koichi Kawamoto; Hidetoshi Eguchi; Taroh Satoh; Masahiro Tanemura; Hiroaki Nagano; Yuichiro Doki; Masaki Mori; Hideshi Ishii

Adipose tissue‐derived mesenchymal stem cells (ADSCs) are multipotent and can differentiate into various cell types, including osteocytes, adipocytes, neural cells, vascular endothelial cells, cardiomyocytes, pancreatic β‐cells, and hepatocytes. Compared with the extraction of other stem cells such as bone marrow‐derived mesenchymal stem cells (BMSCs), that of ADSCs requires minimally invasive techniques. In the field of regenerative medicine, the use of autologous cells is preferable to embryonic stem cells or induced pluripotent stem cells. Therefore, ADSCs are a useful resource for drug screening and regenerative medicine. Here we present the methods and mechanisms underlying the induction of multilineage cells from ADSCs.


International Journal of Oncology | 2013

Aldehyde dehydrogenase high gastric cancer stem cells are resistant to chemotherapy

Shimpei Nishikawa; Masamitsu Konno; Atsushi Hamabe; Shinichiro Hasegawa; Yoshihiro Kano; Katsuya Ohta; Takahito Fukusumi; Daisuke Sakai; Toshihiro Kudo; Naotsugu Haraguchi; Taroh Satoh; Shuji Takiguchi; Masaki Mori; Yuichiro Doki; Hideshi Ishii

Cancer stem cells (CSCs) are known to influence chemoresistance, survival, relapse and metastasis. Aldehyde dehydrogenase (ALDH) functions as an epithelial CSC marker. In the present study, we investigated the involvement of ALDH in gastric CSC maintenance, chemoresistance and survival. Following screening for eight candidate markers (CD13, CD26, CD44, CD90, CD117, CD133, EpCAM and ALDH), five gastric cancer cell lines were found to contain small subpopulations of high ALDH activity (ALDH(high) cells). We also examined the involvement of ALDH(high) cell populations in human primary tumor samples. Immunodeficient NOD/SCID mice were inoculated with tumor tissues obtained from surgical specimens. ALDH(high) cells were found to persist in the xenotransplanted primary tumor samples. in the immunodeficient mice, ALDH(high) cells exhibited a greater sphere‑forming ability in vitro and tumorigenic potential in vivo, compared with subpopulations of low ALDH activity (ALDH(low) cells). Cell cultures treated with 5-fluoro-uracil and cisplatin exhibited higher numbers of ALDH(high) cells. Notch1 and Sonic hedgehog (Shh) expression was also found to increase in ALDH(high) cells compared with ALDH(low) cells. Therefore, it can be concluded that ALDH generates chemoresistance in gastric cancer cells through Notch1 and Shh signaling, suggesting novel treatment targets.


British Journal of Cancer | 2014

CD10 as a novel marker of therapeutic resistance and cancer stem cells in head and neck squamous cell carcinoma.

Takahito Fukusumi; Hideshi Ishii; Masamitsu Konno; T Yasui; S Nakahara; Yoichi Takenaka; Yuki Yamamoto; Shinpei Nishikawa; Yoshihiro Kano; Hisataka Ogawa; Shinichiro Hasegawa; Atsushi Hamabe; Naotsugu Haraguchi; Yuichiro Doki; Masaki Mori; H Inohara

Background:Cancer stem cells (CSCs) are responsible for treatment failure. However, their identification and roles in resistance are not well established in head and neck squamous cell carcinoma (HNSCC).Methods:Three HNSCC cell lines (FaDu, Detroit562 and BICR6) were treated with cisplatin or radiation. Cell surface antigens were analysed by LyoPlate, a novel cell surface antigen array. The expression levels of antigens highly expressed after treatments were further compared between cisplatin-resistant Detroit562 cells and its parental line. Association of the candidate antigen with CSCs properties, namely sphere formation and in vivo tumourigenicity, was also examined.Results:CD10, CD15s, CD146 and CD282 were upregulated across the treated cell lines, while the increased expression of CD10 was prominent in the cisplatin-resistant cell line. Isolation mediated by FACS revealed that the CD10-positive subpopulation was more refractory to cisplatin, fluorouracil and radiation than the CD10-negative subpopulation. It also showed an increased ability to form spheres in vitro and tumours in vivo. Moreover, the CD10-positive subpopulation expressed the CSC marker OCT3/4 at a higher level than that in the CD10-negative subpopulation.Conclusions:CD10 is associated with therapeutic resistance and CSC-like properties of HNSCC. CD10 may serve as a target molecule in the treatment of refractory HNSCC.


International Journal of Oncology | 2013

Depletion of JARID1B induces cellular senescence in human colorectal cancer

Katsuya Ohta; Naotsugu Haraguchi; Yoshihiro Kano; Yoshinori Kagawa; Masamitsu Konno; Shimpei Nishikawa; Atsushi Hamabe; Shinichiro Hasegawa; Hisataka Ogawa; Takahito Fukusumi; Mamoru Uemura; Junichi Nishimura; Taishi Hata; Ichiro Takemasa; Tsunekazu Mizushima; Yuko Noguchi; Miyuki Ozaki; Toshihiro Kudo; Daisuke Sakai; Taroh Satoh; Miwa Fukami; Masaru Ishii; Hirofumi Yamamoto; Yuichiro Doki; Masaki Mori; Hideshi Ishii

The global incidence of colorectal cancer (CRC) is increasing. Although there are emerging epigenetic factors that contribute to the occurrence, development and metastasis of CRC, the biological significance of epigenetic molecular regulation in different subpopulations such as cancer stem cells remains to be elucidated. In this study, we investigated the functional roles of the H3K4 demethylase, jumonji, AT rich interactive domain 1B (JARID1B), an epigenetic factor required for the continuous cell growth of melanomas, in CRC. We found that CD44(+)/aldehyde dehydrogenase (ALDH)(+) slowly proliferating immature CRC stem cell populations expressed relatively low levels of JARID1B and the differentiation marker, CD20, as well as relatively high levels of the tumor suppressor, p16/INK4A. Of note, lentiviral‑mediated continuous JARID1B depletion resulted in the loss of epithelial differentiation and suppressed CRC cell growth, which was associated with the induction of phosphorylation by the c‑Jun N‑terminal kinase (Jnk/Sapk) and senescence‑associated β‑galactosidase activity. Moreover, green fluorescent‑labeled cell tracking indicated that JARID1B‑positive CRC cells had greater tumorigenicity than JARID1B‑negative CRC cells after their subcutaneous inoculation into immunodeficient mice, although JARID1B‑negative CRC cells resumed normal growth after a month, suggesting that continuous JARID1B inhibition is necessary for tumor eradication. Thus, JARID1B plays a role in CRC maintenance. JARID1B may be a novel molecular target for therapy‑resistant cancer cells by the induction of cellular senescence.


Head and Neck-journal for The Sciences and Specialties of The Head and Neck | 2015

Prognostic significance of body mass index before treatment for head and neck cancer.

Yukinori Takenaka; Norihiko Takemoto; Susumu Nakahara; Yoshifumi Yamamoto; Toshimichi Yasui; Atshushi Hanamoto; Takahito Fukusumi; Takahiro Michiba; Hironori Cho; Masashi Yamamoto; Hidenori Inohara

Patients with head and neck cancer frequently experience malnutrition. The purpose of this study was to examine the impact of nutritional status on prognosis and its association with treatment modalities.


Clinical Cancer Research | 2016

Cancer Stem-like Properties in Colorectal Cancer Cells with Low Proteasome Activity.

Koji Munakata; Mamoru Uemura; Shinji Tanaka; Kenji Kawai; Tomohiro Kitahara; Masaaki Miyo; Yoshihiro Kano; Shinpei Nishikawa; Takahito Fukusumi; Yusuke Takahashi; Taishi Hata; Junichi Nishimura; Ichiro Takemasa; Tsunekazu Mizushima; Masakazu Ikenaga; Takeshi Kato; Kohei Murata; John M. Carethers; Hirofumi Yamamoto; Yuichiro Doki; Masaki Mori

Purpose: One of the main reasons for cancer treatment resistance is the existence of cancer stem-like cells (CSCs). Here, we elucidated the relationship between low proteasome activity cells (LPACs) and CSCs. Experimental Design: The human colorectal cancer cell lines HCT116, SW480, DLD1, and KM12SM were engineered to stably express a green fluorescent molecule fused to the degron of ornithine decarboxylase, resulting in an accumulation of the fluorescence in LPACs. LPACs were isolated by flow cytometry. Treatment resistance (radio- and chemotherapy) and the capacity of LPACs to act as CSCs were analyzed. Microarray analysis was performed to reveal genes related to treatment resistance. The prognostic impact of potent genes was examined in 190 patients with colorectal cancer. Results: LPACs had a significantly increased capacity for radioresistance and chemoresistance (5-fluorouracil and oxaliplatin), significantly lower reactive oxygen species activity, and significantly increased sphere formation capacity compared with non-LPACs. The number of cells in the G0–G1 phase was significantly higher among LPACs. Subcutaneous injection of as few as 20 LPACs led to tumor formation in immunologically incompetent mice. Microarray analysis revealed that the expression of EP300-interacting inhibitor of differentiation 3 (EID3) was significantly increased in LPACs. In vitro assay revealed that EID3 positively controlled cell proliferation and treatment resistance. The high expression of EID3 was an adverse prognostic indicator in patients with colorectal cancer (P = 0.0400). Conclusions: LPACs have characteristic treatment resistance and act as CSCs in colorectal cancer. In addition, EID3 is one of the potential regulators of treatment resistance in colorectal cancer and may be a potential therapeutic target. Clin Cancer Res; 22(21); 5277–86. ©2016 AACR.


Molecular and Clinical Oncology | 2013

Jumonji/Arid1b (Jarid1b) protein modulates human esophageal cancer cell growth

Yoshihiro Kano; Masamitsu Konno; Katsuya Ohta; Naotsugu Haraguchi; Shimpei Nishikawa; Yoshinori Kagawa; Atsushi Hamabe; Shinichiro Hasegawa; Hisataka Ogawa; Takahito Fukusumi; Yuko Noguchi; Miyuki Ozaki; Toshihiro Kudo; Daisuke Sakai; Taroh Satoh; Masaru Ishii; Eiichi Mizohata; Takeshi Inoue; Masaki Mori; Yuichiro Doki; Hideshi Ishii

Although esophageal cancer is highly heterogeneous and the involvement of epigenetic regulation of cancer stem cells is highly suspected, the biological significance of epigenetically modified molecules that regulate different subpopulations remains to be firmly established. Using esophageal cancer cells, we investigated the functional roles of the H3K4 demethylase Jumonji/Arid1b (Jarid1b) (Kdm5b/Plu-1/Rbp2-h1), an epigenetic factor that is required for continuous cell growth in melanoma. JARID1B knockdown resulted in the suppression of esophageal cancer cell growth, sphere formation and invasion ability and was associated with loss of epithelial marker expression. However, these inhibitory effects observed on tumor formation were reverted subsequent to subcutaneous inoculation of these cells into immune-deficient mice. These results indicated that JARID1B plays a role in maintaining cancer stem cells in the esophagus and justifies the rationale for studying the effects of continuous inhibition of this epigenetic factor in esophageal cancer.


Acta Oto-laryngologica | 2015

Prognostic significance of serum squamous cell carcinoma antigen in patients with head and neck cancer

Ryusuke Imai; Yukinori Takenaka; Toshimichi Yasui; Susumu Nakahara; Yoshifumi Yamamoto; Atsushi Hanamoto; Norihiko Takemoto; Takahito Fukusumi; Hironori Cho; Masashi Yamamoto; Hidenori Inohara

Abstract Conclusions: Serum squamous cell carcinoma antigen (SCC-Ag) level was an independent prognostic factor for survival in patients with head and neck squamous cell carcinoma (HNSCC), and the prognostic value depended on the carcinoma site. Objectives: To assess the value of SCC-Ag as a prognostic indicator in patients with HNSCC and to determine the effect of primary tumor site on prognosis. Methods: We reviewed 493 patients with HNSCC between 2004 and 2012. The chi-squared test was used to assess associations between SCC-Ag levels and TNM classification. A Cox proportional hazard model was used to assess the hazard ratio of SCC-Ag at different sites for death, and it was analyzed as a continuous variable. Results: The median serum level of SCC-Ag was 1.1 ng/ml (range 0–20). SCC-Ag was significantly higher in patients with advanced T and N classification tumors. Primary sites in the oral cavity, in the hypopharynx, advanced T and N classification, distant metastasis, and SCC-Ag were negatively associated with survival in univariate analysis. Multivariate analysis revealed that SCC-Ag was a significant risk factor for overall survival in cancers of the oral cavity, hypopharynx, and larynx, but not in oropharyngeal cancer.


International Journal of Oncology | 2014

Identification of chemoradiation-resistant osteosarcoma stem cells using an imaging system for proteasome activity

Keisuke Tamari; Kazuhiko Hayashi; Hideshi Ishii; Yoshihiro Kano; Masamitsu Konno; Koichi Kawamoto; Naohiro Nishida; Jun Koseki; Takahito Fukusumi; Shinichiro Hasegawa; Hisataka Ogawa; Atsushi Hamabe; Masaaki Miyo; Kozo Noguchi; Yuji Seo; Yuichiro Doki; Masaki Mori; Kazuhiko Ogawa

Osteosarcoma is the most common primary bone malignancy in pediatric and adolescent populations. Recurrence and metastatic potential can be due to a subpopulation of cells with stem cell-like characteristics, such as tumor-initiating cells (TICs), which maintain the capacity to regenerate entire tumors. Targeting the TICs in osteosarcoma is a promising avenue for the development of new therapies for this devastating disease. TICs are usually quiescent with a low protein turnover, decreased metabolism, and downregulation of proteasome activity. Recently, cancer cells with low proteasome activity have been identified as TICs in several types of cancer. We stably infected two osteosarcoma cell lines, MG-63 and U2-OS, with an expression vector for a fusion protein between the green fluorescent protein, ZsGreen, and the C-terminal degron of the murine ornithine decarboxylase to monitor the 26S proteasome activity in living cells. We separated the osteosarcoma cells with low proteasome activity using fluorescence-activated cell sorting (FACS) and verified whether these ZsGreen+ cells had TIC-like properties. The ZsGreen+ cells showed enhanced sphere formation capacity and underwent asymmetric divisions into ZsGreen+ and ZsGreen- cells, whereas ZsGreen- cells underwent only symmetric divisions into ZsGreen- cells. Moreover, the ZsGreen+ cells were more chemo- and radioresistant. Thus, the present study demonstrated that chemoradiation-resistant TICs can be visualized by this system and suggested the rationale for further study of osteosarcoma stem cells.


Cancer Science | 2012

Reprogramming of gastrointestinal cancer cells

DyahLaksmi Dewi; Hideshi Ishii; Naotsugu Haraguchi; Shimpei Nishikawa; Yoshihiro Kano; Takahito Fukusumi; Katsuya Ohta; Susumu Miyazaki; Miyuki Ozaki; Daisuke Sakai; Taroh Satoh; Hiroaki Nagano; Yuichiro Doki; Masaki Mori

Cell reprogramming reverts cells to multipotent, preprogrammed states by re‐establishing epigenetic markers. It can also induce considerable malignant phenotype modification. Because key events in cancer relapse and metastasis, including epithelial–mesenchymal transition phenotypes, are regulated primarily by reversible and transient epigenetic modifications rather than the accumulation of irreversible and stable genetic abnormalities, studying dynamic mechanisms regulating these biological processes is important. Transcription factors for induced pluripotent stem cells and non‐coding microRNAs allow pluripotent phenotype induction. We present the current knowledge of the possible applications of cell reprogramming in reducing aggressive phenotype expression, which can induce tumor cell hibernation and maintain appropriate phenotypes, thereby minimizing relapse and metastasis after surgical resection of gastrointestinal cancer. (Cancer Sci 2012; 103: 393–399)

Collaboration


Dive into the Takahito Fukusumi's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge